Erste Group analyst Hans Engel downgraded Amgen (AMGN) to Hold from Buy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen to invest additional $300M in U.S. manufacturing network
- Amgen price target lowered to $340 from $351 at Guggenheim
- Amgen Earnings Call Highlights Growth Engines, Tax Risk
- Analyst Reiterates Buy on Amgen After Strong Q1 2026, Raised Guidance and Growing Confidence in MariTide Pipeline
- Amgen Price Target Raised to $425 as Strong Execution and Expanding Pipeline Underpin Maintained Buy Rating